Search Results - "Rhoad, A E"

Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins by Shaw, J.P., Akiyoshi, D.E., Arrigo, D.A., Rhoad, A.E., Sullivan, B., Thomas, J., Genbauffe, F.S., Bacha, P., Nichols, J.C.

“…Elevated expression of the receptor for epidermal growth factor (EGF) is a characteristic of several malignancies including those of the breast, bladder,…”
Get full text

Safety profile and immunogenicity of an inactivated vaccine derived from an attenuated strain of hepatitis A by Ellerbeck, E F, Lewis, J A, Nalin, D, Gershman, K, Miller, W J, Armstrong, M E, Davide, J P, Rhoad, A E, McGuire, B, Calandra, G

“…To determine the safety and immunogenicity of an inactivated hepatitis A vaccine, 56 healthy adult volunteers were randomly assigned to receive an…”
Get more information

A putative sirolimus (rapamycin) effector protein by Chen, Y, Chen, H, Rhoad, A E, Warner, L, Caggiano, T J, Failli, A, Zhang, H, Hsiao, C L, Nakanishi, K, Molnar-Kimber, K L

“…Sirolimus (rapamycin), a new immunosuppressive drug, inhibits proliferation of a wide spectrum of T and B cells. The immunosuppressive mechanism of sirolimus…”
Get more information

Development of the formalin-inactivated hepatitis A vaccine, VAQTA from the live attenuated virus strain CR326F by Armstrong, M E, Giesa, P A, Davide, J P, Redner, F, Waterbury, J A, Rhoad, A E, Keys, R D, Provost, P J, Lewis, J A

“…The development of the formalin-inactivated hepatitis A vaccine, VAQTA, culminates nearly two decades of the basic science studies of VAQTA in hepatitis A…”
Get more information

Cytotoxic properties of DAB sub(486)EGF and DAB sub(389)EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins by Shaw, J P, Akiyoshi, DE, Arrigo, DA, Rhoad, A E, Sullivan, B, Thomas, J, Genbauffe, F S, Bacha, P, Nichols, J C

“…Elevated expression of the receptor for epidermal growth factor (EGF) is a characteristic of several malignancies including those of the breast, bladder,…”
Get full text